• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Marea Therapeutics, Inc.

Marea Therapeutics Enrolls First Participant in Phase 1 Clinical Study Evaluating MAR002 for Acromegaly
August 12, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD
August 04, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Presents Preclinical Data on Novel Growth Hormone Receptor Antagonist Antibody, MAR002, for the Treatment of Acromegaly at ENDO 2025
July 14, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Appoints Shishir Gadam, Ph.D., as Chief Technical Officer
July 01, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Announces Oral Presentation Related to Acromegaly Program at ENDO 2025
June 24, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Appoints Charmi Turner as Senior Vice President, People & Culture
May 20, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
May 16, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93rd EAS Congress
May 07, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Announces Late-Breaking Oral Presentation at the 93rd EAS Congress
April 15, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Forms Clinical Scientific Advisory Board
January 21, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Provides Update on Corporate Progress Including Positive Topline Results from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease and Disclosure of Second Lead Pipeline Program for the Treatment of Acromegaly
January 09, 2025
From Marea Therapeutics, Inc.
Via Business Wire
Marea Therapeutics Expands Management Team and Board of Directors
December 19, 2024
From Marea Therapeutics, Inc.
Via Business Wire
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap